お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
955494

ヒトマイクロバイオーム免疫療法の世界市場と臨床試験の考察:2025年

Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025

出版日: | 発行: KuicK Research | ページ情報: 英文 300 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

ヒトマイクロバイオーム免疫療法の世界市場と臨床試験の考察:2025年
出版日: 2020年09月01日
発行: KuicK Research
ページ情報: 英文 300 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

マイクロバイオームに関する研究は、近年生物学のなかで急速に拡大している分野の1つです。特にマイクロバイオームと免疫学という2つの異なる治療パラダイムの融合は、何百万人もの患者が長年求めていた治療法の開発に道を開いており、多くの研究者が、マイクロバイオームと免疫学的側面に関する研究に関心を寄せています。

当レポートは、世界のヒトマイクロバイオーム免疫療法市場を調査したもので、人体におけるマイクロバイオームの役割とその形態、活動のメカニズム、技術面の要件、マイクロバイオーム免疫療法の各種疾患への応用、業界の動向、市場分析、臨床試験のパイプライン、市場の障壁、競合情勢などの情報を提供しています。

目次

第1章 マイクロバイオームの概要

第2章 人体におけるマイクロバイオームの役割

第3章 マイクロバイオームの多様な形態

  • 腸内マイクロバイオーム
  • 肺マイクロバイオーム
  • 皮膚マイクロバイオーム
  • 他の部分のマイクロバイオーム

第4章 活動のメカニズム

  • 免疫反応の性質
    • 免疫抑制活性
    • 免疫刺激活性
  • マイクロバイオーム機構に関与するメッセンジャー
    • MAMP / PAMP
    • メッセンジャーとしての微生物代謝物
    • メッセンジャーとしての宿主サイトカイン
    • メッセンジャーとしての免疫細胞

第5章 微生物叢の技術要件

  • 使用される技術
    • iChip
    • 人間の腸内微生物生態系のシミュレーター(SHIME)
    • ガットオンチップシステム
    • 結腸幹細胞の構築
  • マイクロバイオームの利用とエンジニアリング
    • 加法的アプローチ
    • 減法的アプローチ

第6章 マイクロバイオーム免疫療法の必要性

第7章 マイクロバイオーム免疫療法の治療応用

  • マイクロバイオーム療法
  • 精密医学
  • 創薬
  • バイオマーカーと治療の最適化

第8章 感染症におけるヒト微生物叢

  • クロストリジウムディフィシルの感染
  • ヘリコバクターピロリの感染
  • 細菌性膣炎
  • HIV感染

第9章 ヒトの微生物叢と肝疾患

  • 非アルコール性脂肪肝疾患(NAFLD)
  • アルコール性肝疾患(ALD)
  • 肝線維症および肝硬変

第10章 ヒトの微生物叢と代謝障害

  • 肥満
  • 2型糖尿病

第11章 ヒトの微生物叢とその他の病気

  • 微生物叢とアレルギー疾患
  • 微生物叢と精神疾患

第12章 がん免疫療法でのマイクロバイオーム

  • がん免疫療法でのマイクロバイオームの役割
  • 発がんと腫瘍抑制におけるマイクロバイオームのメカニズム

第13章 がんタイプ別のマイクロバイオーム応用

  • 胃がん
  • 大腸がん
  • 食道がん
  • 肝細胞がん
  • 黒色腫
  • 固形腫瘍

第14章 腫瘍治療におけるマイクロバイオーム療法の産業的アプローチ

  • 細菌のアプローチ
    • 糞便微生物叢移植(FMT)
    • 合成細菌
    • 微生物培養
  • ワクチンとしてのマイクロバイオーム
  • 小分子としてのマイクロバイオーム
  • ファージウイルスを用いたマイクロバイオーム療法

第15章 世界のヒトマイクロバイオーム市場分析

  • 概要
  • 市場区分
    • 地域別市場
    • 疾患別市場
    • 用途別市場

第16章 マイクロバイオームベース治療の臨床パイプライン

  • 臨床試験におけるマイクロバイオームモジュレーター
  • がん関連の臨床試験
    • 前臨床、創薬段階
    • 実施中の臨床試験
  • FMTに関連する臨床試験
    • 再発性C.ディフィシルの臨床試験
    • 炎症性腸疾患(IBD)の臨床試験
    • その他のFMT関連の臨床試験

第17章 企業別、適応症別、フェーズ別のマイクロバイオーム調節因子の臨床パイプライン

  • 研究段階
  • 前臨床段階
  • 臨床段階
  • フェーズI
  • フェーズI / II
  • フェーズII
  • フェーズII / III
  • フェーズIII

第18章 上市されているマイクロバイオーム調節因子の臨床的考察

  • ナトリウムオリゴマニュラレート:Shanghai Green Valley Pharmaceutical
  • Miya-BM

第19章 世界市場の成長促進要因

第20章 主要企業の投資、買収、協力

第21章 市場の障壁

  • 安定的な生着
  • 臨床関連センサーの開発
  • 遺伝的回路の堅牢性と進化的安定性
  • 規制、安全性、生物学的封じ込め

第22章 世界市場の将来像

第23章 競合情勢

  • 4D Pharma
  • AbbVie
  • AstraZeneca plc
  • Biocodex
  • Bristol Mayer Squibb
  • Corebiome/Diversigen
  • Elogi Bioscience
  • Enterome
  • Ferring Pharmaceuticals
  • Finch Therapeutics
  • Maat Pharma
  • Merck
  • Microbiome Therapeutics
  • Novartis
  • OpenBiome
  • Pfizer
  • Rebiotix
  • Second Genome
  • Seres Therapeutics
  • Symberix
  • Takeda Pharmaceuticals
  • Vedanta Bioscience
図表

List of Figures

  • Figure 1-1: Microbiome Found in Our Body
  • Figure 1-2: Evolution of Microbiome in Medicinal Use
  • Figure 2-1: Composition of Human Microbiota
  • Figure 2-2: Roles of Microbiome in Human Body
  • Figure 3-1: Different Types of Human Microbiome
  • Figure 3-2: Factors Affecting the Development of the Gut Microbiome in Humans
  • Figure 3-3: Study Linking Gut Microbiota & Food Sensitization at 1 year of Age, 2015
  • Figure 4-1: Steps in Mechanism of Microbiome
  • Figure 4-2: Types of Immune Response Produced by Microbiome
  • Figure 4-3: Mechanism of Immunosuppressive Activity of Microbiome
  • Figure 4-4: Processes Facilitating Immunostimulatory Effect of the Gut Microbiota
  • Figure 4-5: Immunostimulatory Action of Microbiome by Increasing the Antigenicity
  • Figure 4-6: Immunostimulatory Action of Microbiome via Adjuvanticity
  • Figure 4-7: Immunostimulatory Action of Microbiome via Bystander T-cell Activation
  • Figure 4-8: Messengers Involved in Mechanism of Microbiome Activity
  • Figure 5-1: Technologies Used in Microbiota Immunotherapy
  • Figure 5-2: New Methods for In-Vitro Simulation of Microbes
  • Figure 5-3: Approaches in Harnessing & Engineering the Microbiome
  • Figure 7-1: Therapeutic Applications of Microbiome
  • Figure 8-1: Impact of Infectious Diseases in Human Microbiota
  • Figure 8-2: Microbiome Imbalance Related Infections
  • Figure 8-3: Mechanism of Microbiome against H. pylori Infection
  • Figure 8-4: Management of H. pylori Infection using Single & Multi Strain Probiotic Microbiome
  • Figure 8-5: Process of Vaginal Microbiota Transplantation (VMT)
  • Figure 8-6: Mechanism of Different Microbiome therapeutics against HIV infection
  • Figure 9-1: Hypothetical Pathway: Role of Gut Microbiota Dysbiosis in Liver Diseases
  • Figure 9-2: Microbiome Related Liver Disorders
  • Figure 9-3: Management of Non-Alcoholic Fatty Liver Disease using Probiotic Microbiome
  • Figure 9-4: Management of Alcoholic Liver Disease using Probiotic Microbiome
  • Figure 9-5: Management of Liver Fibrosis & Cirrhosis using Probiotic Microbiome
  • Figure 10-1: Metabolic Disorders Related to Gut Microbiota
  • Figure 10-2: Relation of Microbiome with the Metabolic Disorders
  • Figure 10-3: Factors Responsible for Obesity
  • Figure 10-4: Mechanism of Probiotics against Obesity
  • Figure 10-5: Management of Obesity using Probiotic Microbiome
  • Figure 10-6: Influence of Disturbed Gut Microbiome on Diabetes
  • Figure 10-7: Management of Type 2 Diabetes using Probiotic Microbiome
  • Figure 11-1: Allergic Diseases Influenced by Microbiome
  • Figure 11-2: Management of Allergic Diseases using Microbiome Preparations
  • Figure 11-3: Microbiome Associated Psychiatric Disorders
  • Figure 11-4: Management of Psychiatric Disorders using Microbiome
  • Figure 12-1: Microbiome at the Intersection between Physiology & Pathology in Cancer
  • Figure 12-2: Microbiome Action in Tumor Formation vs. Tumor Suppression
  • Figure 13-1: Microbiome Applications on Basis of Cancer Types
  • Figure 13-2: Management of Colorectal Cancer using Microbiomes
  • Figure 13-3: Anticancer Mechanism of Microbiome Metabolite (Butyrate)
  • Figure 13-4: Microbiome of Normal Esophagus vs. GERD-Barrett's Esophagus
  • Figure 13-5: Management of Esophageal Cancer using Microbiome
  • Figure 13-6: Role of Disturbed Microbiome in Development of Hepatocellular Carcinoma
  • Figure 14-1: Industrial Approaches of Microbiome Therapy in Oncology
  • Figure 14-2: Number of Companies Involved in Different Anticancer Approaches of Microbiome, 2019
  • Figure 14-3: Companies Involved in Different Anticancer Approaches of Microbiome (%), 2019
  • Figure 14-4: Types of Bacterial Approaches in Microbiome Technology
  • Figure 14-5: Number of Companies Involved in Different Bacterial Approaches, 2019
  • Figure 14-6: Procedure of Fecal Microbiota Transplantation (FMT)
  • Figure 14-7: Various Engineered Circuits of Synthetic Bacteria
  • Figure 14-8: Applications of Phage in Cancer Biology & Treatment
  • Figure 15-1: Global - Human Microbiome Immunology Therapeutics Market Size (US$ Million), 2018 to 2025
  • Figure 15-2: Global - Human Microbiome Market Size & FMT Market Size (US$ Million), 2019
  • Figure 15-3: Global - Human Microbiome Market Segmentation
  • Figure 15-4: Global - Microbiome Therapeutic Market Share (%) - US,Europe & Rest of World, 2019 & 2025
  • Figure 15-5: USA - Human Microbiome Market Size (US$ Million), 2019 & 2025
  • Figure 15-6: Europe - Human Microbiome Market Size (US$ Million), 2019 & 2025
  • Figure 15-7: Global - Human Microbiome Market Share by Diseases (%), 2025
  • Figure 15-8: Global - Human Microbiome Market by Application (%), 2019 & 2025
  • Figure 16-1: Global - Microbiome Modulator Drug Clinical Pipeline by Phase, 2020
  • Figure 16-2: Global - Microbiome Modulator Drug Clinical Pipeline by Country, 2020
  • Figure 16-3: Global - Microbiome Modulator Drug Clinical Pipeline by Drug Class, 2020
  • Figure 16-4: Global - Microbiome Modulator Drug Clinical Pipeline by Drug Company, 2020
  • Figure 16-5: Global - Microbiome Modulator Drug Clinical Pipeline by Indication, 2020
  • Figure 16-6: Number of Microbiome-Based Cancer Therapeutics in Discovery & Preclinical Phase of Development, 2019
  • Figure 16-7: Companies Conducting Discovery Program of Anticancer Microbiome
  • Figure 16-8: Companies Conducting Preclinical Trials of Anticancer Microbiome
  • Figure 16-9: Active Clinical Trials of Anticancer Microbiome
  • Figure 16-10: Global - Number of Clinical Trial Studies Related to Fecal Microbiota Transplant in Different Phases,2020
  • Figure 16-11: Global - Fecal Microbiota Transplant in Different Phases of Clinical Trial (%), 2020
  • Figure 16-12: Global - Status of Active FMT Clinical Trials, 2020
  • Figure 16-13: Global - FMT Clinical Trial in Management of C. difficile Infection, 2020
  • Figure 16-14: Global - FMT Clinical Trial in Management of Inflammatory bowel Disease, 2020
  • Figure 19-1: Drivers of Microbiome Immunotherapeutics
  • Figure 20-1: MaaT Pharma - Investment Received by Year (EUR/US$ Million), 2015, 2016 & 2020
  • Figure 20-2: Finch Therapeutics - Investments Received by Year (US$ Million), 2016 - 2019
  • Figure 20-3: Rebiotix - Investment Received by Year (US$ Million), 2011, 2014 & 2017
  • Figure 20-4: Enterome - Investment Received by Year (EUR/US$ Million), 2011,2012, 2014, 2016, 2017 & 2020
  • Figure 20-5: Second Genome - Investments by Year (US$ Million), 2011, 2013 & 2016
  • Figure 21-1: Challenges in the Path of Microbiome Immunotherapy Technology
目次

"Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" Report Highlights:

  • Global & Regional Market Insight
  • Global Human Microbiome Immunology Therapeutics Market: >US$ 1 Billion by 2025
  • US Dominates Global Market Landscape: >60% Market Share
  • Comprehensive Information on Ongoing Clinical Trials & Potential Drug Candidates
  • Global Microbiome Modulator Drugs in Clinical Pipeline: >80 Drug in Trials
  • Therapeutic Applications of Microbiome Immunology by Indication
  • Clinical Trial Studies Related to Fecal Microbiota Transplant: > 250 Clinical Trials

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome's role in immunology practices is to transform the world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

Essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then unsuccessful implication of immunology therapies driven treatments led to exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

All over the world, the amalgamation of the two has been well accepted and appreciated by the patients, physicians and the clinicians. Investigation of all the working sides of microbiome and how it plays an important role in boosting the manipulated immune cells have recently started in large numbers as the technology available in the medical field allows to capture it accurately. To facilitate the microbiome and immunology community in order to extract the best and trending opportunities that are stemmed into the microbiome research, the experts from both the relevant disciplines are analyzing it through clinical researches and surveys. Further, the area is getting supported by 86 different clinical trials getting conducted in different countries.

"Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology. The science that is related with microbiome has high interdisciplinary and various opportunities that somehow have remained hidden in the medical world. It is believed that the opportunities and all the desirable tangible benefits microbiome is capable of delivering when combined with immunology is large and needs coordinated and constructive approach. The call to the two different sectors i.e. microbiology and immunology is estimated to unlock the potential and promising benefits of microbiome. The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge

Table of Contents

1. Overview of Microbiome

  • 1.1 Introduction to Microbiome
  • 1.2 History & Evolution of Microbiome

2. Role of Microbiome in Human Body

3. Microbiome: Various Forms

  • 3.1 Gut Microbiome
  • 3.2 Lung Microbiome
  • 3.3 Skin Microbiome
  • 3.4 Microbiome in Other Parts of the Body

4. Mechanism of Microbiome Activity

  • 4.1 Nature of Immune Response
    • 4.1.1 Immunosuppressive Activity
    • 4.1.2 Immunostimulatory Activity
  • 4.2 Messengers Involves in Microbiome Mechanism
    • 4.2.1 MAMPs/PAMPs
    • 4.2.2 Microbial Metabolites As Messengers
    • 4.2.3 Host Cytokines As Messengers
    • 4.2.4 Immune Cells As Messengers

5. Technological Requirement for Microbiota

  • 5.1 Technologies Used
    • 5.1.1 iChip
    • 5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)
    • 5.1.3 Gut-on-a-Chip System
    • 5.1.4 Colonic Stem Cell Construction
  • 5.2 Harnessing & Engineering the Microbiome
    • 5.2.1 Additive Approaches
    • 5.2.2 Subtractive Approaches

6. Need for Microbiome Immunology

7. Therapeutic Applications of Microbiome Immunology

  • 7.1 Microbiome Therapy
  • 7.2 Precision Medicine
  • 7.3 Drug discovery
  • 7.4 Biomarkers & Therapy Optimization

8. Human Microbiota in Infectious Diseases

  • 8.1 Infection with Clostridium Difficile
  • 8.2 Infection with Helicobacter Pylori
  • 8.3 Bacterial Vaginosis
  • 8.4 Infection with HIV

9. The Human Microbiota & Liver Diseases

  • 9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)
  • 9.2 Alcoholic Liver Diseases (ALD)
  • 9.3 Liver Fibrosis & Cirrhosis

10. The Human Microbiota & Metabolic Disorders

  • 10.1 Obesity
  • 10.2 Type 2 Diabetes

11. The Human Microbiota & Other Diseases

  • 11.1 Microbiota & Allergic Diseases
  • 11.2 Microbiota & Psychiatric Diseases

12. Microbiome in Immuno Oncology

  • 12.1 Role of Microbiome in Immuno Oncology
  • 12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression

13. Microbiome Application by Cancer Types

  • 13.1 Gastric Cancer
  • 13.2 Colorectal Cancer
  • 13.3 Esophageal Cancer
  • 13.4 Hepatocellular Carcinoma
  • 13.5 Melanoma
  • 13.6 Solid Tumors

14. Industrial Approaches of Microbiome Therapy in Oncology

  • 14.1 Bacterial Approaches
    • 14.1.1 Fecal Microbiota Transplantation (FMT)
    • 14.1.2 Synthetic Bacteria
    • 14.1.3 Microbial Culture
  • 14.2 Microbiome as Vaccine
  • 14.3 Microbiome as Small Molecules
  • 14.4 Microbiome Therapy using Phage Virus

15. Global Human Microbiome Market Analysis

  • 15.1 Overview
  • 15.2 Human Microbiome Market Segmentation
    • 15.2.1 Regional Segmentation
    • 15.2.2 Disease Based Segmentation
    • 15.2.3 Segmentation by Application

16. Clinical Pipeline of Microbiome Based Therapy

  • 16.1 Microbiome Modulators in Clinical Trial
  • 16.2 Cancer Related Clinical Trials
    • 16.2.1 Preclinical & Discovery Phase
    • 16.2.2 Active Clinical Trials
  • 16.3 Clinical Trial Related To FMT
    • 16.3.1 Clinical Trial for Recurrent C. difficile
    • 16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)
    • 16.3.3 Other FMT Related Clinical Trials

17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase

  • 17.1 Research
  • 17.2 Preclinical
  • 17.3 Clinical
  • 17.4 Phase-I
  • 17.5 Phase-I/II
  • 17.6 Phase-II
  • 17.7 Phase-II/III
  • 17.8 Phase-III

18. Marketed Microbiome Modulators Clinical Insight

  • 18.1 Sodium Oligomannurarate - Shanghai Green Valley Pharmaceutical
  • 18.2 Miya-BM

19. Global Microbiome Immunology Therapeutics Market Growth Drivers

20. Microbiome Technology - Investments, Acquisitions & Collaborations by Leading Microbiome Companies

21. Blockades in the Microbiome Immunology Market

  • 21.1 Stable Engraftment
  • 21.2 Development of Clinically Relevant Sensors
  • 21.3 Robustness and Evolutionary Stability of Genetic Circuits
  • 21.4 Regulation, Safety and Biocontainment

22. Global Microbiome Immunology Market Future Panorama

23. Competitive Landscape

  • 23.1 4D Pharma
  • 23.2 AbbVie
  • 23.3 AstraZeneca plc
  • 23.4 Biocodex
  • 23.5 Bristol Mayer Squibb
  • 23.6 Corebiome/Diversigen
  • 23.7 Elogi Bioscience
  • 23.8 Enterome
  • 23.9 Ferring Pharmaceuticals
  • 23.10 Finch Therapeutics
  • 23.11 Maat Pharma
  • 23.12 Merck
  • 23.13 Microbiome Therapeutics
  • 23.14 Novartis
  • 23.15 OpenBiome
  • 23.16 Pfizer
  • 23.17 Rebiotix
  • 23.18 Second Genome
  • 23.19 Seres Therapeutics
  • 23.20 Symberix
  • 23.21 Takeda Pharmaceuticals
  • 23.22 Vedanta Bioscience
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.